Inflammasome inhibition: putting out the fire

Cell Metab. 2015 Apr 7;21(4):513-4. doi: 10.1016/j.cmet.2015.03.012.

Abstract

NLRP3-inflammasome activates caspase-1 and processes pro-IL-1β and pro-IL-18 into the active cytokines. Two recent studies describe specific inhibitors of NLRP3 inflammasome that inhibit IL-1β release and inflammation. The specificity and potency of these compounds gives hope that a targeted approach to inhibit NLRP3-driven inflammation may be just around the corner.

Publication types

  • Comment

MeSH terms

  • 3-Hydroxybutyric Acid / pharmacology*
  • Animals
  • Carrier Proteins / antagonists & inhibitors*
  • Caspase 1 / drug effects*
  • Cryopyrin-Associated Periodic Syndromes / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Female
  • Heterocyclic Compounds, 4 or More Rings / therapeutic use*
  • Humans
  • Inflammasomes / antagonists & inhibitors*
  • Interleukin-1beta / drug effects*
  • Male
  • Monocytes / drug effects*
  • Multiple Sclerosis*
  • Sulfones / therapeutic use*

Substances

  • Carrier Proteins
  • Heterocyclic Compounds, 4 or More Rings
  • Inflammasomes
  • Interleukin-1beta
  • Sulfones
  • Caspase 1
  • 3-Hydroxybutyric Acid